NCT01709838View on ClinicalTrials.gov

Efficacy and Safety Study of Deferasirox in Patients With Non-transfusion Dependent Thalassemia

PHASE4CompletedINTERVENTIONAL
Enrollment

134

Participants

Timeline

Start Date

December 6, 2012

Primary Completion Date

January 3, 2015

Study Completion Date

January 17, 2019

Conditions
Non-transfusion Dependent Thalassemia
Interventions
DRUG

deferasirox

Deferasirox dispersible tablets at strengths of 125 mg, 250 mg, and 500 mg were administered by oral daily dosing.

Trial Locations (11)

1006

Novartis Investigative Site, Tunis

10700

Novartis Investigative Site, Bangkok

20122

Novartis Investigative Site, Milan

34093

Novartis Investigative Site, Istanbul

35040

Novartis Investigative Site, Izmir

530021

Novartis Investigative Site, Nanning

115 27

Novartis Investigative Site, Goudi-Athens

09121

Novartis Investigative Site, Cagliari

PO BOX 213

Novartis Investigative Site, Hazmiyeh

01330

Novartis Investigative Site, Adana

NW1 2PJ

Novartis Investigative Site, London

Sponsors
All Listed Sponsors
lead

Novartis Pharmaceuticals

INDUSTRY